… This is, in our opinion, a correct approach, although there are other potential risks to be
taken into account, for example, thrombocytopenia, a common alteration in COVID-19 patients …

… for heparin failure with particular relevance to COVID‐19. We … COVID‐19 (ie, occurrence
of thrombotic events on‐heparin … potential, or (3) an inability to reach desired heparin plasma …

… unfractionated heparin or low molecule weight heparin could decrease mortality in COVID-19
… Of particular interest is the potential application of HP in COVID-19 treatment, as well as for …

… swab‐culture positive for COVID‐19, were affected by acute … the growing evidence of potential
thrombotic events we decided … observed in patients with COVID‐19 could be related to an …

… of heparin as an anti-viral, antithrombotic and anti-inflammatory drug in the early stage of the
COVID-19 … widely discussed is the antiviral potential provided by heparins. Previous to the …

… potential to decrease thrombotic risk in COVID-19 without substantially increasing major
bleed risk. Globally, more than 20 trials have been initiated comparing escalated or treatment-…

… weight heparin (LMWH) administration in COVID-19 … potential association between different
dosages of LMWH enoxaparin administration and mortality among hospitalized COVID-19 …

… Thus, structurally defined heparin/HS and their mimetics might serve as potential drugs
by competing with cell surface HS for the prevention of viral adhesion and modulation of …

… the potential of HBP in predicting sepsis in COVID-19, … molecular weight heparin (LMWH) to
hospitalized COVID-19 patients … off-target benefit of heparin administration in COVID-19 is its …

… -19. We find that COVID-19 patients administered unfractionated Heparin but not
Enoxaparin have higher rates of 28-day mortality, even after controlling for potential …